Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
Brown, Sarah R., Hall, Andrew, Buckley, Hannah L., Flanagan, Louise, Gonzalez de Castro, David, Farnell, Kate, Moss, Laura, Gregory, Rebecca, Newbold, Kate, Du, Yong, Flux, Glenn, Wadsley, JonathanVolume:
19
Langue:
english
Journal:
BMC Cancer
DOI:
10.1186/s12885-019-5541-4
Date:
December, 2019
Fichier:
PDF, 901 KB
english, 2019